Kornimate/medical-research-clean huggingface dataset:
ecmo braile biomédica® in covid-19 patients

Conditions: COVID-19

Summary: retrospective data collection to evaluate the gas transfer capacity of the braile biomédica® oxyprime® ecmo brcoating® membrane oxygenator in covid-19 patients during the pandemic.

multicenter, retrospective, non-comparative, non-randomized study to assess the clinical performance of the oxyprime® ecmo brcoating® membrane oxygenator in adult patients with covid-19

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old, with a previous diagnosis of covid-19, who were placed on ecmo using the oxyprime® ecmo braile biomédica® membrane oxygenator, from march 2020 to july 2022, following the instructions for use (ifu) of the products. exclusion criteria: * patients without a diagnosis of covid-19

Keywords: ecmo covid-19 membrane oxygenator
pain and suction curettage

Conditions: Curettage; Analgesia; Paracervical Block; Paracetamol

Summary: aim of the study was to investigate the analgesic efficacy of preoperative oral dexketoprofen trometamol, intravenous paracetamol, lidocaine spray and paracervical block with ultracaine on curettage procedure.


Eligibility criteria:
inclusion criteria: * pregnant participants between 35-48 days of gestation (5 to 7 weeks of gestation) pregnant participants with a single viable intrauterine pregnancy requesting termination of pregnancy. exclusion criteria: incomplete abortions, diabetes mellitus, tendency to bleed such as thrombocytopenia, factor deficiency and functional disorders of platelets... etc, pelvic infection, known cervical stenosis, significantly impaired respiratory or cardiac conduction functions, active liver disease, renal disease, previous adverse reaction to any of the drugs used in the study, and patients who are unable to understand how to score a 10-cm visual analog scale (vas) pain score. moreover, patients who described chronic pelvic pain prior to the study or patients who rated their pain level on a continuous 100-mm vas different from 0 (no pain) just before the study were not included into study.

Keywords: curettage analgesia paracervical block paracetamol lidocaine dexketoprofen trometamol
gemcitabine, cisplatin, and amifostine following surgery in treating patients with locally advanced bladder cancer

Conditions: Bladder Cancer; Drug/Agent Toxicity by Tissue/Organ

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. purpose: phase ii trial to study the effectiveness of combining gemcitabine, cisplatin, and amifostine following surgery in treating patients who have locally advanced bladder cancer.

objectives: * determine the toxicity of adjuvant gemcitabine and cisplatin with amifostine cytoprotection in patients with completely resected locally advanced bladder cancer. * compare recurrence rate in these patients when treated with this regimen to historical control patients who had a cystectomy performed by the same surgeon. outline: patients receive gemcitabine iv over 30 minutes on days 1, 8, and 15, and cisplatin iv over 60 minutes and amifostine iv over 15 minutes on day 1. treatment continues every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. patients are followed every 6 months. projected accrual: a total of 19-42 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * completely resected locally advanced bladder cancer * t2-4, n0-2 * post radical cystectomy with no gross residual disease * no evidence of metastases by ct of chest, abdomen, and pelvis patient characteristics: age: * 18 and over performance status: * karnofsky 70-100 life expectancy: * at least 12 weeks hematopoietic: * wbc at least 3,500/mm\^3 * platelet count at least 100,000/mm\^3 * hemoglobin at least 9.0 g/dl (transfusion allowed) hepatic: * bilirubin no greater than 2 times upper limit of normal (uln) * ast and alt no greater than 3 times uln renal: * creatinine no greater than 2.0 mg/dl or * creatinine clearance at least 50 ml/min other: * not pregnant or nursing * fertile patients must use effective contraception during and for 3 months after study participation * no active infection * no serious concurrent systemic disorders that would preclude study participation * no metastatic cancer in past 5 years prior concurrent therapy: biologic therapy: * no concurrent immunotherapy chemotherapy: * no other concurrent chemotherapy endocrine therapy: * no concurrent hormonal therapy except contraceptives and replacement steroids radiotherapy: * no concurrent radiotherapy surgery: * see disease characteristics * at least 4 but no more than 8 weeks since radical cystectomy other: * no other concurrent experimental medications

Keywords: stage ii bladder cancer stage iii bladder cancer stage iv bladder cancer drug/agent toxicity by tissue/organ
molecular mechanism of pop kidney yin deficiency syndrome from the interventional effects of clcf1

Conditions: Postmenopausal Osteoporosis

Summary: this study use rt-pcr and western blot technique to detect the expression of clcf1 mrna and protein in pop kidney yin deficiency group and healthy group to verify the relevance between clcf1 and pop the kidney yin deficiency syndrome.through sirna and overexpression,observe the mrna and protein 's expression of cbp、jak1、stat4 and the protein phosphorylation of jak1、stat4 in jak-stat signal to reveal the clcf1 regulate the cbp's mechanism.use the liuwei dihuang pills to detect the effect of treatment ,compare use or not the liuwei dihuang pills to detect the mrna and protein 's expression of clcf1、cbp etc.aim to clarify the pop kidney yin deficiency molecular mechanism.


Eligibility criteria:
inclusion criteria: * the participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent. * female ages 45 to 75 had gone through natural menopause before two years * in accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney yin deficiency syndrome differentiation of traditional chinese medicine certificate; * in accordance with the western medicine diagnostic criteria; * in accordance with tcm diagnostic methods; .if any of the above answers are no, the subjects couldn't in the study. exclusion criteria: * do not accord with standard of the western medicine diagnosis and tcm diagnostic methods * age: \ 76 years old; * with hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; late or deformity, disability, loss of labor; * with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases; * psychosis or alzheimer's patients; * nearly three months, the use of hormone replacement therapy (hrt) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.; * this medicine allergic constitution or composition of known to have allergies; * in a critical condition, it's difficult to make exact evaluators to efficacy and safety of the new drugs;

Keywords: postmenopausal osteoporosis; kidney yin deficiency syndrome; liuwei dihuang pill; clcf1; jak - stat signal pathway
abdominal wall transplant

Conditions: Transplant;Failure,Kidney; Transplant; Failure, Liver; Transplant; Failure, Bowel; Abdominal Wall Defect; Abdominal Wall Fistula; Abdominal Wall Hernia; Abdominal Wall Injury

Summary: the purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects. abdominal wall transplantation may be performed alone or in combination with another transplant.

within this protocol we propose to perform abdominal wall transplantation in 5 subjects, either as an isolated abdominal wall or in combination with another organ transplant. each subject will be followed for a study period of 18 months. participants receiving an isolated abdominal wall or abdominal wall in combination with another organ transplant will receive the standard immunosuppression therapy as the non-vascularized composite allograft organ transplant. these patients will be studied to determine efficacy of the abdominal wall transplant to restore function of the defective abdominal wall for a study period of 18 months at duke university medical center.

Eligibility criteria:
inclusion criteria: * candidates between 18-65 years old * willingness and legal ability to give consent * abdominal wall in combination with another organ transplant: they must be eligible for the non-vascularized composite allograft organ transplant at duke exclusion criteria: * malignancy at evaluation or history of malignancy that precludes transplantation * pregnancy: women who are of childbearing potential must have a negative serum pregnancy test within 48 hours of transplant and agree to use reliable contraception with two contraceptive methods for a minimum of 2 years following abdominal wall transplantation. subjects seeking to become pregnant following 2 years will be made aware during the consent process that the effect of pregnancy on the transplanted abdominal wall and vice versa is unknown. * medical exclusion criteria for general anesthesia * ongoing substance abuse or history of untreated substance abuse

Keywords: research transplant abdominal wall hernia
a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of inv-9956 in adult patients with advanced metastatic castration resistant prostate cancer

Conditions: Advanced Metastatic Castration Resistant Prostate Cancer

Summary: this is a phase 1a, first-in-human, open-label dose-escalation study to determine the rdr and/or mtd, and to assess the dlt of inv-9956. the safety, tolerability, pk/pd, and preliminary antitumor activity of inv-9956 will be assessed in adult patients with advanced mcrpc.

this is a phase 1a, first-in-human, open-label dose-escalation study to determine the rdr and/or mtd, and to assess the dlt of inv-9956. the safety, tolerability, pk/pd, and preliminary antitumor activity of inv-9956 will be assessed in adult patients with advanced mcrpc. the study will be conducted in 3 stages: stage 1: dose escalation; stage 2: dose expansion; stage 3 (optional): dose escalation beyond the optimal dose. the total number of patients enrolled will depend upon the number of dose-escalation cohorts and the number of doses evaluated in stage 2. the investigational drug will be co-administered with dexamethasone and fludrocortisone acetate as corticosteroid replacement therapy.

Eligibility criteria:
inclusion criteria: 1. written informed consent obtained. 2. male aged ≥ 18 years. 3. histologically confirmed adenocarcinoma of the prostate. 4. castration resistant prostate cancer with serum testosterone \<50 ng/dl. 5. metastatic disease. 6. ongoing androgen deprivation therapy with gnrh analogue or antagonist, or have had bilateral orchiectomy. 7. received at least one prior line of taxane-based chemotherapy and at least one line of hormonal ar targeted therapy (eg, abiraterone, enzalutamide). patients who have refused or were intolerant to taxane-based chemotherapy may be enrolled. 8. ecog performance status 0-1. 9. adequate marrow, liver and kidney function. 10. inr ≤1.5. 11. able to swallow study treatment. 12. has a life expectancy of \> 3 months. exclusion criteria: 1. have a medical condition such as crohn's disease or have undergone significant surgery to the gastrointestinal tract that could impair absorption or that could result in short bowel syndrome with diarrhea due to malabsorption. 2. history of pituitary or adrenal dysfunction. 3. poorly controlled diabetes mellitus. 4. clinically significant abnormality in serum potassium and sodium. 5. have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor. 6. active or unstable cardio-/cerebro-vascular disease, including thromboembolic events. 7. history of congestive heart failure; cardiac disease, myocardial infarction within 6 months prior to enrollment. 8. prolonged qtcf interval. 9. active infection or other medical condition that would make corticosteroid contraindicated.

Keywords: mcrpc prostate cancer
chronic sucrose intake, markers of health and biomarker identification

Conditions: Dietary Exposure; Metabolic Disturbance

Summary: with free sugar intake proving to be of a concern within the general public, discovery and validation of a new biomarker will allow for more consistent measurement of sucrose intake. furthermore, using a multi-omic approach the investigators will identify metabolic perturbations to the metabolome and proteome.

excessive free sugar intake is of concern within the general public, as intakes have been associated with weight gain and cardiovascular disease. average intakes are over double that of the 5% of total energy intake that is recommended by the science advisory committee on nutrition, but intakes are calculated from observational measures that lack sensitivity and discovery and validation of a new biomarker from biological fluids may allow for more specific measurement and a better understanding of intake:disease relationships. furthermore, understanding the biochemistry of sucrose intake will allow the identification of damage occurrence and alternative metabolic pathways, as well as novel protein damage that occur with chronic sucrose exposure. this study aims to identify a biomarker of chronic sucrose consumption using metabolite profiling technology. the study will be composed of a randomised controlled intervention trial, in which participants will be required to consume an amount of sucrose (0-120g/d) every day for 7 days and provide biofluid samples (urine and blood) before the initiation, during and following the intervention; that will undergo metabolic analysis. furthermore, participants will have their anthropometrics and dietary intake monitored throughout the study. the biomarker will also be validated against the dietary information and correlated with indices of health and sucrose-induced damage. the investigators will also monitor the feasibility and acceptability of chronic sucrose intake during the intervention.

Eligibility criteria:
inclusion criteria: * age 19-64, healthy diagnosis exclusion criteria: * gastrointestinal issues, doesn't consume sugar
ashcom shoulder system and its related instruments

Conditions: Rotator Cuff Injuries; Shoulder Pain; Arthropathy; Traumatic; Arthroplasty Complications

Summary: the objectives of this study are to confirm safety, performance and clinical benefits of the ashcom shoulder system and its related instruments by analysis of standard scoring systems, radiographs and adverse event records.

this study is a multicenter, prospective, non-controlled post-market clinical follow-up study involving orthopaedic surgeons skilled in reverse shoulder arthroplasty procedures. a minimum of three study centers will be involved. a total number of 97 implants will be included into the study. the primary endpoint is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using kaplan meier method. the safety of the system will be assessed by monitoring the frequency and incidence of adverse events. the secondary endpoint is defined by the performance and clinical benefits of the ashcom shoulder system at 5 years, which is assessed by the constant and murley score. assessments of the overall pain, functional performance, survival, quality of life and radiographic parameters of all enrolled study subjects will be evaluated in addition.

Eligibility criteria:
inclusion criteria: * patient is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program. * patient has given written consent to take part in the study by signing the "patient consent form". * patient is 18-80 years of age, inclusive. * patient is skeletally mature. * patient requires a primary, fracture or revision reverse total shoulder replacement for the relief of pain and has significant disability due to gross rotator cuff deficiency. * patient's joint is anatomically and structurally suited to receive the selected implants. * patient has a functional deltoid muscle. exclusion criteria: * patient is unwilling or unable to give consent or to comply with the follow-up program. * patients who have any condition which would in the judgement of the investigator place the patient at undue risk or interfere with the study. any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them. * patient is known to be pregnant or breastfeeding. * patient is a vulnerable subject. * patient meets at least one of the contraindications: * signs of infection * significant injury to the upper brachial plexus * non-functional deltoid muscle * insufficient quality and/or quantity of glenoid or humeral bone * any neuromuscular or vascular disease compromising the affected limb that would endanger the success of the intervention
isoenergetic high intensity interval training and moderate intensity training in adults with type i diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: type 1 diabetes (t1d) is associated with increased risk of poor cardiometabolic health. regular exercise is recommended for optimal management of comorbidities in t1d. unique barriers to exercise exist for t1d, including fear of hypoglycemia, unpredictable glycemic excursions with exercise, and inadequate knowledge about exercise. unlike traditional moderate intensity continuous training (mict) which requires extended periods of time, high intensity interval training (hiit) requires minimal time (\~10 minutes of exercise per session), with the potential to rapidly stimulate mitochondrial biogenesis and metabolism. the extent to which these exercise strategies alter metabolomic signatures of carbohydrate, fat, and amino acid metabolism in t1d is unknown. the overall goal of the proposed project is to identify the acute metabolic effects and physiological modifiers of hiit compared to mict and control (con) using metabolomic profiling and cardiometabolic assessments in 14 adults with t1d. using a randomized cross-over approach, the primary aim is to compare the metabolomics response immediately post, 1 hr post, and glycemic control through 48 hrs after hiit, compared to mict matched for total energy expenditure, versus a no exercise con. an additional aim will be to characterize the influence of biological sex and physiological outcomes (i.e. body composition, lean mass, visceral fat) on the metabolomics profile of these subjects. outcomes from the present study, with existing data from our team, will lay the foundation for a larger diet and exercise lifestyle intervention that will ultimately lead to changes in clinical practice to co-manage glycemia and cardiometabolic comorbidities.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of presumed autoimmune t1d, receiving daily insulin * last hemoglobin a1c \<9% * 18-51 years * duration of t1d: ≥ 1 year * body mass index (bmi) \<30 kg/m\^2 * generally healthy, with no conditions that could influence the outcome of the trial, and in the judgement of the investigators is a good candidate for the study, based on a review of health history exclusion criteria: * physician diagnosis of active diabetic retinopathy that could be worsened by exercise * physician diagnosis of peripheral neuropathy with insensate feet * physician diagnosis of autonomic neuropathy * medications: beta-blockers, agents that affect hepatic glucose production such as beta adrenergic agonists, xanthine derivatives; any hypoglycemic agent other than insulin. * severe hypoglycemic event defined as the individual requiring a third party of hospitalization in the last 6 months * diabetic ketoacidosis in the last 6 months * has a closed-loop pump and not willing to use manual mode * physician diagnosis of cardiovascular disease that would affect exercise tolerance * currently doing hiit * severely impaired hearing or speech * pregnancy
transcriptional and proteomic analysis of acute kidney injury

Conditions: Acute Kidney Injury

Summary: acute kidney injury is associated with worsened outcome for critically ill patients. sepsis-associated and non-septic cardiothoracic surgery associated aki have been reported, nonetheless, precise pathomechanistic differences as well as detectability of transcriptional and proteomic changes in correlation with imaging and plasma markers are unclear.

acute kidney injury is a common and detrimental finding in critically ill/sepsis patients as well as non-septic patients post cardiothoracic surgery. in many cases renal replacement therapy is required and an acute kidney injury is linked to increased morbidity and mortality in intensive care patients. using routinely obtained clinical samples as well as imaging data, this observational trial investigates the transcriptomic and proteomic determinants detectable in septic and non-septic aki patient subsets and their correlation with outcome and aki diagnostic parameters.

Eligibility criteria:
* inclusion criteria: * study consent; * kdigo\>=2; * vasoplegia and/or sepsis or elective nephrectomy. * exclusion criteria: * age\<18 years; * pregnancy/nursing; * preexisting ckd with egfr\<60m/min; * dialysis; former ogran transplantation; * hiv; hematologic malignancies; * immunsuppression; * 4h post biopsy non-pausable effective anticoagulation; * pre-existing coagulopathy
indacaterol in heart failure patients: any role on lung fluid regulation

Conditions: Heart Failure

Summary: the purposes of this study are: 1. to confirm safety of indacaterol in stable heart failure. 2. to determine whether beta 2 alveolar receptor stimulation by indacaterol is able to ameliorate lung diffusion in heart failure patients treated with beta blockers. 3. to compare the effects of indacaterol in patients treated with a non-selective beta blocker (carvedilol) and a beta 1-selective beta blocker (bisoprolol).


Eligibility criteria:
inclusion criteria: * male and female adults aged ≥ 18 years who have signed an informed consent form. * patients with light chronic obstructive pulmonary disease never treated with bronchodilator drugs * co-operative patients * patients with a clinical diagnosis of chronic heart failure (hf) * chronic myeloproliferative disorder with ejection fraction \< 40% with b blockers therapy since at least 2 months. optimized and individually tailored drug treatment including b blocker (carvedilol or bisoprolol) * capability of performing cardiopulmonary exercise test and lung diffusion test exclusion criteria: history or clinical documentation of: * pulmonary embolism * primary valvular heart disease * pericardial disease * severe obstructive lung disease * significant peripheral vascular disease * exercise-induced angina, st changes, or severe arrhythmias. * patients with diabetes type i or uncontrolled diabetes type ii including patients with a history of blood glucose levels consistently outside the normal range or hba1c \> 8.0 % of total hemoglobin measured. * use of bronchodilators. * patients with a history (or family history) of long qt syndrome or whose corrected qt interval interval (fridericia) measured at visit 2 is prolonged: \>450 ms (males) or \>470 ms (females) as assessed by the central electrocardiogram (ecg) interpretation.